title: Ð¡ÑÐµÐ¿ÐµÐ½Ñ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð¸Ð½ÑÑÐ¾Ð½Ð° 1 Ð³ÐµÐ½Ð° SNCA Ð² CD45+ ÐºÐ»ÐµÑÐºÐ°Ñ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸ Ð¿ÑÐ¸ Ð±Ð¾Ð»ÐµÐ·Ð½Ð¸ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: Methylation status of SNCA-intron1 in CD45+ peripheral blood cells in Parkinson's disease
Creators: name: ÐÐ¸ÑÑÑÐ¾Ð²Ð°, ÐÐºÐ°ÑÐµÑÐ¸Ð½Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2020
Subjects: Ð±Ð¾Ð»ÐµÐ·Ð½Ñ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°
Ð°Ð»ÑÑÐ°-ÑÐ¸Ð½ÑÐºÐ»ÐµÐ¸Ð½
Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ðµ ÐÐÐ
SNCA
Ð´Ð¾ÑÐ°Ð¼Ð¸Ð½
Ð»Ð¸Ð¼ÑÐ¾ÑÐ¸ÑÑ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸
CD45+
Parkinson's disease
alfa-synuclein
DNA methylation
dopamine
peripheral blood lymphocytes

description: ÐÐ»ÑÑÐµÐ²ÑÐ¼ Ð·Ð²ÐµÐ½Ð¾Ð¼ Ð¿Ð°ÑÐ¾Ð³ÐµÐ½ÐµÐ·Ð° Ð±Ð¾Ð»ÐµÐ·Ð½Ð¸ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð° (ÐÐ) ÑÐ²Ð»ÑÐµÑÑÑ Ð¾Ð»Ð¸Ð³Ð¾Ð¼ÐµÑÐ¸Ð·Ð°ÑÐ¸Ñ Ð½ÐµÐ±Ð¾Ð»ÑÑÐ¾Ð³Ð¾ Ð¿ÑÐµÑÐ¸Ð½Ð°Ð¿ÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð±ÐµÐ»ÐºÐ° Ð°Ð»ÑÑÐ°-ÑÐ¸Ð½ÑÐºÐ»ÐµÐ¸Ð½Ð° (SNCA) Ð² ÑÐ¸ÑÐ¾Ð¿Ð»Ð°Ð·Ð¼Ðµ Ð´Ð¾ÑÐ°Ð¼Ð¸Ð½ÐµÑÐ³Ð¸ÑÐµÑÐºÐ¸Ñ Ð½ÐµÐ¹ÑÐ¾Ð½Ð¾Ð² ÑÐµÑÐ½Ð¾Ð¹ ÑÑÐ±ÑÑÐ°Ð½ÑÐ¸Ð¸ Ð³Ð¾Ð»Ð¾Ð²Ð½Ð¾Ð³Ð¾ Ð¼Ð¾Ð·Ð³Ð°. ÐÑÐµÐ´Ð¿Ð¾Ð»Ð°Ð³Ð°ÐµÑÑÑ, ÑÑÐ¾ Ð½Ð° Ð°Ð³ÑÐµÐ³Ð°ÑÐ¸Ñ Ð±ÐµÐ»ÐºÐ° Ð¼Ð¾Ð¶ÐµÑ Ð²Ð»Ð¸ÑÑÑ Ð½Ð°ÑÑÑÐµÐ½Ð¸Ðµ ÑÐ¿Ð¸Ð³ÐµÐ½ÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÑÐµÐ³ÑÐ»ÑÑÐ¸Ð¸ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð³ÐµÐ½Ð° SNCA, Ð² ÑÐ¾Ð¼ ÑÐ¸ÑÐ»Ðµ Ð·Ð° ÑÑÐµÑ Ð²Ð¾Ð·Ð´ÐµÐ¹ÑÑÐ²Ð¸Ñ Ð´Ð¾ÑÐ°Ð¼Ð¸Ð½Ð° (ÐÐ). Ð Ð´Ð°Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÐµ Ð¾ÑÐµÐ½Ð¸Ð²Ð°Ð»Ð°ÑÑ ÑÑÐµÐ¿ÐµÐ½Ñ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð¸Ð½ÑÑÐ¾Ð½Ð° 1 Ð³ÐµÐ½Ð° SNCA Ð¸ ÑÑÐ¾Ð²ÐµÐ½Ñ ÐµÐ³Ð¾ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð² CD45+ ÐºÐ»ÐµÑÐºÐ°Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐÐ Ð¸ Ð¸Ð½Ð´Ð¸Ð²Ð¸Ð´ÑÑÐ¼Ð¾Ð² ÐºÐ¾Ð½ÑÑÐ¾Ð»ÑÐ½Ð¾Ð¹ Ð³ÑÑÐ¿Ð¿Ñ, Ð° ÑÐ°ÐºÐ¶Ðµ Ð²Ð»Ð¸ÑÐ½Ð¸Ðµ ÐÐ Ð½Ð° Ð´Ð°Ð½Ð½ÑÐµ Ð¿Ð¾ÐºÐ°Ð·Ð°ÑÐµÐ»Ð¸ Ð² ÑÐºÐ°Ð·Ð°Ð½Ð½ÑÑ Ð³ÑÑÐ¿Ð¿Ð°Ñ in vitro. ÐÑÐµÐ½ÐºÐ° ÑÑÐµÐ¿ÐµÐ½Ð¸ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð¸Ð½ÑÑÐ¾Ð½Ð° 1 Ð³ÐµÐ½Ð° SNCA Ð¸ ÑÑÐ¾Ð²Ð½Ñ ÐµÐ³Ð¾ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð¿ÑÐ¾Ð²Ð¾Ð´Ð¸Ð»Ð°ÑÑ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ Ð¼Ð°ÑÑÐ¾Ð²Ð¾Ð³Ð¾ Ð¿Ð°ÑÐ°Ð»Ð»ÐµÐ»ÑÐ½Ð¾Ð³Ð¾ ÑÐµÐºÐ²ÐµÐ½Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð±Ð¸ÑÑÐ»ÑÑÐ¸Ñ-ÐºÐ¾Ð½Ð²ÐµÑÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð½Ð¾Ð¹ ÐÐÐ Ð¸ ÐÐ¦Ð  Ð² ÑÐµÐ¶Ð¸Ð¼Ðµ ÑÐµÐ°Ð»ÑÐ½Ð¾Ð³Ð¾ Ð²ÑÐµÐ¼ÐµÐ½Ð¸, ÑÐ¾Ð¾ÑÐ²ÐµÑÑÑÐ²ÐµÐ½Ð½Ð¾. Ð ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ Ð¾Ð±Ð½Ð°ÑÑÐ¶ÐµÐ½Ð¾ ÑÐ½Ð¸Ð¶ÐµÐ½Ð¸Ðµ ÑÑÐµÐ¿ÐµÐ½Ð¸ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð¸Ð½ÑÑÐ¾Ð½Ð° 1 Ð³ÐµÐ½Ð° SNCA Ð² ÐºÑÐ»ÑÑÐ¸Ð²Ð¸ÑÑÐµÐ¼ÑÑ Ð±ÐµÐ· ÐÐ Ð»Ð¸Ð¼ÑÐ¾ÑÐ¸ÑÐ°Ñ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸ (ÐÐÐ) Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐÐ Ð¿Ð¾ ÑÑÐ°Ð²Ð½ÐµÐ½Ð¸Ñ Ñ ÐºÐ¾Ð½ÑÑÐ¾Ð»ÐµÐ¼. ÐÑÑÐ²Ð»ÐµÐ½Ð¾, ÑÑÐ¾ ÐÐ Ð½Ðµ Ð²Ð»Ð¸ÑÐµÑ Ð½Ð° ÑÑÐµÐ¿ÐµÐ½Ñ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð¸Ð½ÑÑÐ¾Ð½Ð° 1 Ð³ÐµÐ½Ð° SNCA Ð² ÐºÑÐ»ÑÑÐ¸Ð²Ð¸ÑÑÐµÐ¼ÑÑ ÐÐÐ ÐºÐ°Ðº Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐÐ, ÑÐ°Ðº Ð¸ Ð¸Ð½Ð´Ð¸Ð²Ð¸Ð´ÑÑÐ¼Ð¾Ð² ÐºÐ¾Ð½ÑÑÐ¾Ð»ÑÐ½Ð¾Ð¹ Ð³ÑÑÐ¿Ð¿Ñ. Ð ÑÐ¾ Ð¶Ðµ Ð²ÑÐµÐ¼Ñ Ð½Ðµ Ð±ÑÐ»Ð¾ Ð¾Ð±Ð½Ð°ÑÑÐ¶ÐµÐ½Ð¾ Ð°ÑÑÐ¾ÑÐ¸Ð°ÑÐ¸Ð¸ ÐÐ Ñ Ð¸Ð·Ð¼ÐµÐ½ÐµÐ½Ð¸ÐµÐ¼ ÑÑÐµÐ¿ÐµÐ½Ð¸ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð¸Ð½ÑÑÐ¾Ð½Ð° 1 Ð³ÐµÐ½Ð° SNCA Ð² CD45+ ÐºÐ»ÐµÑÐºÐ°Ñ. ÐÑÑÐ²Ð»ÐµÐ½Ð¾ Ð¸Ð·Ð¼ÐµÐ½ÐµÐ½Ð¸Ðµ ÑÑÐµÐ¿ÐµÐ½Ð¸ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð¾ÑÐ´ÐµÐ»ÑÐ½ÑÑ CpG-Ð¾ÑÑÑÐ¾Ð²ÐºÐ¾Ð² Ð¸Ð½ÑÑÐ¾Ð½Ð° 1 Ð³ÐµÐ½Ð° SNCA Ð¿ÑÐ¸ ÐÐ ÐºÐ°Ðº Ð² CD45+ ÐºÐ»ÐµÑÐºÐ°Ñ, ÑÐ°Ðº Ð¸ Ð² ÐºÑÐ»ÑÑÐ¸Ð²Ð¸ÑÑÐµÐ¼ÑÑ ÐÐÐ. ÐÐ¾Ð»ÑÑÐµÐ½Ð½ÑÐµ Ð´Ð°Ð½Ð½ÑÐµ ÑÐ²Ð¸Ð´ÐµÑÐµÐ»ÑÑÑÐ²ÑÑÑ Ð¾Ð± Ð¾ÑÑÑÑÑÑÐ²Ð¸Ð¸ Ð°ÑÑÐ¾ÑÐ¸Ð°ÑÐ¸Ð¸ ÑÑÐµÐ¿ÐµÐ½Ð¸ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð¸Ð½ÑÑÐ¾Ð½Ð° 1 Ð³ÐµÐ½Ð° SNCA Ð² CD45+ ÐºÐ»ÐµÑÐºÐ°Ñ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸ Ð¸ ÐÐ, Ð° ÑÐ°ÐºÐ¶Ðµ Ð²Ð»Ð¸ÑÐ½Ð¸Ñ ÐÐ Ð½Ð° ÑÑÐµÐ¿ÐµÐ½Ñ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ ÑÐºÐ°Ð·Ð°Ð½Ð½Ð¾Ð¹ Ð¾Ð±Ð»Ð°ÑÑÐ¸ Ð´Ð°Ð½Ð½Ð¾Ð³Ð¾ Ð³ÐµÐ½Ð° Ð¿ÑÐ¸ ÐÐ in vitro.
description: Itâs known that the key link in the pathogenesis of Parkinson's disease (PD) is the oligomerization of a small presynaptic alpha-synuclein protein (SNCA) in the cytoplasm of dopaminergic neurons of the substantia nigra. Itâs assumed that protein aggregation can be affected by a violation of the epigenetic regulation of SNCA gene expression, including due to exposure to dopamine (DA). In this work, we evaluated the methylation status of of SNCA-intron1 and its expression level in CD45 + cells of patients with PD and control individuals, as well as the effect of DA on these parameters in these groups in vitro. Real-time polymerase chain reaction was used to measure of the SNCA gene expression. Methylation state of SNCA-intron1 was analyzed using high-resolution bisulphite sequencing. As a result of the study, a decrease in the methylation status of SNCA-intron1 in the cultured without DA peripheral blood lymphocytes (PBL) of patients with PD was found compared with the control. It was revealed that DA doesnât affect the methylation status of SNCA-intron1 in cultured PBL both in patients with PD and in individuals of the control group. At the same time, there was no association of PD with a change in the methylation status of SNCA-intron1 in CD45 + cells. A change was detected in methylation status of individual CpG islands of SNCA-intron1 in PD both in CD45 + cells and in cultured PBL. The data obtained indicate the absence of association of the methylation status of SNCA-intron1 in CD45 + cells of peripheral blood and PD, as well as the effect of DA on the methylation status of this region of this gene in PD in vitro.